Beijing TB strains undermine BCG-trained immunity early after infection

Tuberculosis is caused by Mycobacterium tuberculosis, but not all strains behave the same. In particular, a modern clade known as Lineage 2–Beijing (L2-B) has become common in Asia and is now found around the world. Epidemiologists and vaccine researchers have noticed that L2-B can be associated with reduced protection from the bacille Calmette Guérin (BCG) vaccine, but the ways it avoids vaccine-induced defenses have been unclear. In work led by Naomi J. Daniels, researchers set out to test how L2-B interacts with immune responses that are primed by BCG. They used a controlled animal model in which mice were vaccinated with BCG and later challenged by inhaling bacteria. The challenges were performed with clinical isolates that were geographically matched: some from the Lineage 2–Beijing clade and others from Lineage 4. By comparing the two groups, the team aimed to find whether and how L2-B circumvents the immunity that BCG is supposed to provide, and to identify the timing and cellular mechanisms of any immune escape.

The group combined laboratory and tissue-level analyses to pinpoint immune differences after infection. In vitro, BCG-trained alveolar macrophages showed impaired control of L2-B growth, indicating that cells thought to be 'trained' by BCG were less able to limit the Beijing strains. In the vaccinated mouse lungs, the researchers applied spatial transcriptomic profiling to examine gene expression patterns across infected tissue. This approach revealed broad transcriptional reprogramming in areas of infection, and crucially it showed selective suppression of pathways essential for macrophage activation and trained innate immunity. Those same patterns of immune dysregulation were detected in human samples: peripheral blood from BCG-vaccinated household contacts of L2-B smear-positive TB patients displayed similar signs of altered immune response. Taken together, the data link a laboratory defect in macrophage control, tissue-scale changes in gene expression, and matching signals in human blood to show lineage-specific immune evasion by L2-B.

These findings point to a strain-specific way that tuberculosis can dodge vaccine-primed innate defenses. By showing that Lineage 2–Beijing strains can blunt key activation pathways in macrophages and reshape gene expression in infected lungs early after infection, the study highlights components of immunity that BCG normally induces and that L2-B appears to target. The parallel observations in vaccinated household contacts suggest that this is not just a laboratory artifact but may have relevance for people exposed to L2-B in the real world. Practically, the work supports reconsidering current TB vaccine strategies: vaccines and evaluations that assume uniform bacterial behavior may miss lineage-specific vulnerabilities. Future vaccine development and public health planning may need to take pathogen diversity into account to restore or improve protection against L2-B strains.